Click here to visit Company website

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. The majority of its sales are concentrated in the therapeutic areas of immunology/neurology, primarily through its intravenous immune globulin (IGIV) product for the treatment of primary immune deficiency, CIDP, and pulmonology, through its alpha-1 proteinase inhibitor (A1PI) product for the treatment of alpha-1 antitrypsin deficiency-related emphysema.